Urgent.News

the world's headlines, one feed

Health & Medicine

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

(MedPage Today) -- Liposomal daunorubicin and cytarabine (Vyxeos) didn't hold up to standard daunorubicin/cytarabine induction therapy in children and young adults with newly diagnosed acute myeloid leukemia (AML), a phase III trial from the Children...

Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML

We haven't written up this one. MedPage Today has the full story — the link below goes straight to it.

Read the original at medpagetoday.com →

More in Health & Medicine